Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
Public ClinicalTrials.gov record NCT01887366. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Once-Weekly Intra-Muscular Injections of TV-1380 (150 mg/Week or 300 mg/Week) as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to assess the efficacy and safety of TV-1380 \[Recombinant human serum albumin (HSA) mutated butyrylcholinesterase (AlbuBChE)\] in facilitating abstinence in cocaine-dependent subjects.
Study identification
- NCT ID
- NCT01887366
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 208 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2013 (Type not available)
- Primary completion
- Sep 2014 (Actual)
- Completion
- Oct 2014 (Actual)
- Last update posted
- Nov 5, 2015
2013 – 2014
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 10663 | Los Angeles | California | — | — |
| Teva Investigational Site 10665 | Oceanside | California | — | — |
| Teva Investigational Site 10659 | San Francisco | California | — | — |
| Teva Investigational Site 10746 | Torrance | California | — | — |
| Teva Investigational Site 10664 | North Miami | Florida | — | — |
| Teva Investigational Site 10661 | Boston | Massachusetts | — | — |
| Teva Investigational Site 10668 | New Bedford | Massachusetts | — | — |
| Teva Investigational Site 10747 | St Louis | Missouri | — | — |
| Teva Investigational Site 10745 | Las Vagas | Nevada | — | — |
| Teva Investigational Site 10667 | Marlton | New Jersey | — | — |
| Teva Investigational Site 10662 | Columbus | Ohio | — | — |
| Teva Investigational Site 10660 | Pittsburgh | Pennsylvania | — | — |
| Teva Investigational Site 10658 | Charleston | South Carolina | — | — |
| Teva Investigational Site 10666 | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01887366, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2015 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01887366 live on ClinicalTrials.gov.